Lilly Company Profile

✉ Email this page to a colleague

LILLY has one hundred and five approved drugs.

There is one US patent protecting LILLY drugs.

There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-six supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	BETALIN S	thiamine hydrochloride	INJECTABLE;INJECTION	080853-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Lilly	PROZAC	fluoxetine hydrochloride	TABLET;ORAL	020974-002	Mar 9, 1999		DISCN	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-002	Nov 26, 2002	AB	RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	5,641,790	⤷ Try a Trial
Lilly	DECABID	indecainide hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019693-001	Dec 29, 1989	4,389,393	⤷ Try a Trial
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-002	Sep 7, 2007	5,217,974*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg	➤ Subscribe	2005-01-10
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2005-11-01
➤ Subscribe	For Injection	2 g/vial	➤ Subscribe	2007-08-24
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2008-02-04
➤ Subscribe	For Injection	750 mg/vial	➤ Subscribe	2016-10-06
➤ Subscribe	Tablets	2.5 mg	➤ Subscribe	2008-10-14
➤ Subscribe	Delayed-release Capsules	20 mg, 30 mg and 60 mg	➤ Subscribe	2008-08-04
➤ Subscribe	Capsules	10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg	➤ Subscribe	2007-05-29
➤ Subscribe	Capsules	3 mg/25 mg	➤ Subscribe	2008-05-08
➤ Subscribe	For Injection	1g/vial	➤ Subscribe	2005-11-14
➤ Subscribe	For Injection	100 mg/vial	➤ Subscribe	2008-07-01
➤ Subscribe	For Injection	1000 mg/vial	➤ Subscribe	2012-06-27
➤ Subscribe	Injection	250 mcg/mL, 2.4 mL prefilled Pen	➤ Subscribe	2015-07-27
➤ Subscribe	Tablets	5 mg, 10 mg and 20 mg	➤ Subscribe	2007-11-21
➤ Subscribe	Delayed-release Capsules	40 mg	➤ Subscribe	2012-05-10

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Hungary	E045180	⤷ Try a Trial
Eurasian Patent Organization	009497	⤷ Try a Trial
Portugal	1732629	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1280520	14/2015	Austria	⤷ Try a Trial	PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
0933372	SPC/GB08/018	United Kingdom	⤷ Try a Trial	PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
0740668	C00740668/01	Switzerland	⤷ Try a Trial	PRODUCT NAME: TADALAFILUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56018 04.05.2004
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.